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Abstract
[Cu(hnc)2(H2O)2] Æ 2H2O (1) [hncH = 4-hydroxy-3-nitro-2H-chromen-2-one] and [Ag(hnc)] (2) were prepared by deprotonating
the hydroxy group of hncH with NaOH and then adding copper(II) chloride dihydrate and silver(I) nitrate, respectively. [Ag(hmnc)]
(3) was synthesised in a similar manner [hmncH = 7-hydroxy-8-nitro-3-methyl-2H-chromen-2-one]. The mixed-ligand Ag(I) com-
plex [Ag(phen)2hnc] (4) was prepared by treating silver(I) nitrate with 1,10-phenanthroline (phen) (1:1) and subsequent reaction with
a solution containing hncH and NaOH. Molecular structures of 1 and 2 were determined by X-ray crystallography. The asymmetric
unit in 1 contains two molecules of water in addition to one molecule of the copper complex. In 2 the asymmetric unit comprises one
hnc ligand moiety bonded in a bidentate fashion to the silver(I) ion with additional interactions from three other coumarin ligands.
The geometry is best described as pentagonal bipyramidal. While none of the coumarin-based ligands or the free copper salt showed
any significant anti-microbial activity, AgNO3 and its phen and coumarin complexes exhibited good anti-microbial activity, partic-
ularly against the clinically important methicillin-resistant Staphylococcus aureus (MRSA) bacterium and also demonstrated good
activity, comparable to that of the commercial fungicides clortrimazole and ketoconazole, against a clinical isolate of the fungal
pathogen Candida albicans.
 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Interest in coumarin chemistry has flourished for
many years, largely as a result of the wide spectrum
of uses for coumarin derivatives. Such derivatives have
been proven to function as anti-coagulants [1], anti-
bacterial agents [2], antifungal agents [3], biological
inhibitors [4], chemotherapeutics [5] and as bio-analyt-
ical reagents [6]. Recently, an area of coumarin chem-
istry that is increasing in importance concerns
biologically active metal complexes of coumarin-based
ligands. In general, coordination of metal ions to ther-
apeutic agents improves their efficacy and accelerates
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bioactivity. In this context, a broad array of medicinal
applications of metal complexes has been investigated
and several recent reviews summarize advances in this
field [7–12]. Previous studies have been carried out on
the chemotherapeutic and anti-microbial activity of a
limited number of metal-coumarin complexes. Kumar
et al. [13,14] synthesised a number of hydroxy-
substituted coumarin transition metal complexes, which
included a series of complexes of hydroxynitrocouma-
rins, hydroxyaminocoumarins, 4-hydroxy-3-phenylazo-
coumarin and 8-acetyl-4-methylumbelliferone. The
complexes were tested for their antifungal ability using
Rhizoctonia solani (causative organism for sheath
blight in rice plants) and also against the bacterial
strain Escherichia coli. Their results demonstrated that
metal complexes displayed greater inhibition of micro-
bial growth than free ligands and, furthermore, activ-
ity was comparable to that of the commercial
bactericide, Agrimycin-100. Kostova et al. [15–20]
have carried out a series of studies on the cytotoxicity
of lanthanide and zirconium complexes of hydroxyl-
ated coumarins and reported IC50 values of 50–
300 lM for the neodymium complexes of bis-couma-
rins when screened using HL-60, Hl-60/Dox and
SKW-3 cell lines. A recent study by Nath et al. [21]
has shown that triorganotin(IV) derivatives of
7-hydroxycoumarin, and their adducts with 1,10-phe-
nanthroline (phen), have potent anti-inflammatory
activity.
We have previously studied the chemotherapeutic
potential of a series of metal-free hydroxynitrocouma-
rins [22–27]. These compounds were tested against
both normal human and neoplastic skin cell lines
and were found to be selectively cytotoxic to human
skin malignant melanocytes and renal cell carcinoma.
An earlier study had found that 7-hydroxy-8-nitro-
coumarin was cytotoxic to a panel of cell lines includ-
ing K562 (human erythroleukemic), HL-60 (human
promyelocytic) and CHrC5 (Chinese hamster ovary)
[28]. It was thought that the biological activity exhib-
ited by the compounds could be increased by their
coordination to a metal centre and a study to investi-
gate this proposal is currently underway. However, a
tandem study on the antimicrobial activity of a series
of these metal complexes was carried out given the re-
sults obtained by Kumar et al. [13,14] on related cou-
marin complexes.
The present paper details the synthesis of a Cu(II)
and a number of Ag(I) hydroxynitrocoumarin com-
plexes and their subsequent in vitro screening against
a range of Gram positive and Gram negative bacte-
rial strains and also against a clinical isolate of Can-
dida albicans. In addition, a silver(I) complex
containing hydroxynitrocoumarin and phen ligands
also isolated and its anti-microbial activity was
investigated.
2. Experimental
2.1. Chemistry
Chemicals and solvents were purchased from
Sigma–Aldrich Co. (Dorset, UK), with the exception
of 4-methyl-7-hydroxy-8-nitro-chomen-2-one (hmncH)
which was obtained from Lancaster (Lancashire,
UK) and used without further purification. Infrared
spectra of solids (in a KBr matrix) were recorded in
the region 4000–400 cm1 on a Nicolet Impact 410
Fourier-Transform Infrared spectrophotometer. A
JEOL JNM-LA300 FT-NMR spectrometer was used
to record 1H NMR spectra (5 to 15 ppm from
TMS) and 13C NMR spectra (33 to 233 ppm from
TMS) as solutions in d6-DMSO. Microanalytical data
were provided by the Microanalytical Laboratory, Na-
tional University of Ireland, Belfield, Dublin 4. Solid
state magnetic susceptibility measurements were car-
ried out at room temperature in the Dublin Institute
of Technology, Cathal Brugha Street, Dublin 1, using
a Johnson Matthey Magnetic Susceptibility Balance
with [HgCo(SCN)4] being used as a reference
standard.
2.1.1. [Cu(hnc)2(H2O)2] Æ 2H2O (1)
A solution of CuCl2 Æ 2H2O (0.082 g, 0.48 mmol) in
water (10 cm3) was added to a solution of NaOH
(0.04 g, 0.97 mmol) and 4-hydroxy-3-nitro-2H-chro-
men-2-one (hncH) (0.20 g, 0.97 mmol) in water
(10 cm3) and the mixture left to stir for 2 h. After stand-
ing for 2 days, a green product precipitated which was
filtered off, washed with cold water and methanol and
then dried in a vacuum oven at 40 C. The solid was
recrystallised from water. Yield: 0.20 g (81%). The com-
plex was soluble in DMSO, and sparingly soluble in eth-
anol, methanol and water. Anal. Calc. C, 42.24; H, 2.32;
N, 5.47; Cu, 12.77. Found: C, 43.04; H, 2.08; N, 5.27;
Cu, 12.46%. IR (KBr): 3471, 3447, 2950, 1686, 1671,
1613, 1552, 1467, 1376, 1343, 1281, 1261, 1212 cm1.
leff = 2.01 BM.
2.1.2. [Ag(hnc)] (2)
A solution of AgNO3 (0.164 g, 0.96 mmol) in water
(10 cm3) was added to a solution of NaOH (0.04 g,
0.97 mmol) and hncH (0.20 g, 0.97 mmol) in water
(10 cm3) and the mixture left to stir for 2 h. Upon stand-
ing a yellow precipitate formed, which was filtered off,
washed with methanol and cold water and then dried
under vacuum at 40 C. The solid was recrystallised
from water. Yield: 0.14 g (46%). The complex was solu-
ble in DMSO, and sparingly soluble in methanol, etha-
nol and water. Anal. Calc. C, 34.42; H, 1.28; N, 4.46%.
Found: C, 34.33; H, 1.16; N, 4.28%. 1H NMR: Ar–H5
(7.88 ppm, 1H, ddd, J = 7.88, 1.83, 0.36 Hz), Ar–H6
(7.22 ppm, 1H, brd, J = 7.53 Hz), Ar–H7 (7.51 ppm,
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1H, dt, J = 8.61, 7.5, 1.83 Hz) Ar–H8 (7.17 ppm, 1H,
ddd, J = 8.82, 1.11, 0.36 Hz); 13C NMR: C2, 167.6;
C3, 120.47; C4, 152.44; C4a, 122.29; C5, 125.59; C6,
122.89; C7, 132.08; C8, 116.02; C8a, 157.58 ppm. IR
(KBr): 1687, 1610, 1584, 1462, 1434, 1347, 1308,
1286 cm1.
2.1.3. [Ag(hmnc)] (3)
A solution of AgNO3 (0.169 g, 0.995 mmol) in water
(10 cm3) was added over a period of 10 min to a solution
of NaOH (0.04 g, 0.97 mmol) and hmncH (0.20 g,
0.90 mmol) in water (10 cm3) at room temperature. A
brown/red solid immediately precipitated and the result-
ing suspension was left to stir for 1 h. The solid was fil-
tered off, washed with cold water and dried under
vacuum at 40C. Yield: 0.180 g (61%). The complex
was soluble in DMSO and insoluble in all other com-
mon solvents. Anal. Calc. C, 36.16; H, 1.84; N, 4.27.
Found: C, 37.08; H, 1.80; N, 4.15%. 1H NMR: CH3
(2.3 ppm, 3H, d, J = 0.7 Hz), Vinyl–H, (5.7 ppm, 1H,
d, J = 0.7 Hz), Ar–H5 (6.3-7.3 ppm, 1H, d, J =
9.3 Hz), Ar–H6 (6.33 ppm, 1H, d, J = 9.3 Hz) 13C
NMR: C2, 166.44; C3, 103.0; C4, 159.81; C4a, 102.38;
C5, 125.9; C6, 120.3; C7, 154.48; C8, 130; C8a, 148.21;
CH3, 18 ppm. IR (KBr): 3412, 1719, 1617, 1588, 1541,
1506, 1420, 1369, 1329, 1276 cm1.
2.1.4. [Ag(phen)2hnc] (4)
A solution of AgNO3 (0.123 g, 0.72 mmol) in water
(10 cm3) was added to a solution of phen (0.131 g,
0.72 mmol) in ethanol (10 cm3) giving an immediate
yellow precipitate. This suspension was then added
to a solution comprising hncH (0.15 g, 0.72 mmol)
and NaOH (0.029 g, 0.72 mmol) in water (10 cm3)
over a 10 min period at room temperature. The mix-
ture was then refluxed for 1 h and the resulting yellow
solid was filtered off, washed with cold water and
dried under vacuum at 40 C. Yield: 0.180 g (74%).
The complex was soluble in DMSO, methanol and
ethanol and sparingly soluble in water. Anal. Calc.
C, 58.7; H, 2.98; N, 10.38. Found: C, 57.7; H, 2.94;
N, 9.96%. 1H NMR: Phen–H H2, (9.17 ppm, 4H,
dd, J = 4.6, 1.6 Hz), H3, (8.01 ppm, 4H, dd, J = 4.6,
8.2 Hz), H4, (8.78 ppm, 4H, dd, J = 1.6, 8.3 Hz) H5
(8.22 ppm, 4H, s) hnc protons Ar–H5 (7.86 ppm,
1H, ddd, J = 7.7, 1.8, 0.4 Hz) Ar–H6 (7.20 ppm, 1H,
dt, J = 7.7, 1.11 Hz) Ar–H7 (7.49 ppm, 1H, dt,
J = 8.61, 1.7 Hz), Ar–H8 (7.47 ppm, 1H, dd, J = 8.6,
1.1 Hz) IR (KBr): 3442, 1685, 1619, 1570, 1509,
1462, 1421, 1297, 1208 cm1.
2.2. Antifungal susceptibility testing
A clinical isolate of C. albicans ATCC 10231 was
obtained from American Type Culture Collection
(Maryland, USA). Antifungal susceptibility testing
was performed using broth microdilution assays
according to the National Committee for Clinical
Laboratory standards (Document M27-A2) protocol
with slight modifications. M27-A2 method was altered
by substituting Antibiotic Medium 3 (Oxoid Ltd.) for
RPMI 1640 medium. Using this method minimum
inhibitory concentrations (MICs) were determined by
UV spectrophotometer at 405 nm by comparing the
turbidity of growth in each well. MIC80 is defined as
the lowest concentration of drug that inhibits growth
by 80%.
2.3. Anti-microbial testing
All bacterial isolates were obtained from clinical sam-
ples: Staphylococcus aureus (urinary track infection),
methicillin-resistant S. aureus (wound infection), Staph-
ylococcus simulans (facial skin), Micrococcus luteus
(facial skin) E. coli (gastro-intestinal tract), Bacillus
oleronius (facial skin), Pantoea agglumerans (facial skin).
The Gram-positive strains used were S. aureus (SA),
methycillin-resistant S. aureus (MRSA), S. simulans
(S.Sim.) and M. luteus (Ml) and the Gram negative
strains were E. coli (E.Coli), B. oleronius (BO) and
P. agglumerans (PA).
The coumarin complexes were tested against four
Gram positive and three Gram negative strains to
determine their antibacterial activity. Bacterial strains
were grown overnight in nutrient broth medium at
30 C and 200 rpm in an orbital incubator. The absor-
bance of these cultures was measured at 660 nm and
cultures were diluted to an optical density of 0.1. The
cell suspension (100 ll) was added to the wells of a
96 well plate containing novel coumarin derivative dis-
solved in nutrient broth medium in serial dilutions
from 100 to 0.25 lg/ml. Plates were incubated at
30 C for 24 h and the optical density was measured
spectrophotometrically (Dynex Technology) at 660 nm.
3. Results and discussion
3.1. Complex synthesis and spectral characterisation
[Cu(hnc)2(H2O)2] Æ 2H2O (1) and [Ag(hnc)] (2) were
prepared in aqueous solution by deprotonating the hy-
droxy group of hncH with NaOH and then adding cop-
per(II) chloride dihydrate and silver(I) nitrate,
respectively. [Ag(hmnc)] (3) was synthesised in a similar
manner. The mixed-ligand Ag(I) complex [Ag-
(phen)2hnc] (4) was prepared by treating silver(I) nitrate
with phen (1:1) and subsequent reaction with a solution
containing hncH and NaOH.
The infrared spectra of the complexes and free li-
gands were recorded in KBr matrix. The most signif-
icant changes in absorption frequencies between the
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free and coordinated ligands are the masym(NO2)
stretch of the nitro group, the m(C@O) and m(C–O)
stretches of the lactone (in hncH), and the phenoxy
alcohol m(O–H) stretch (in hmncH). The values for
the masym nitro for all of the complexes (ca.
1580 cm1), when compared with that of the free li-
gand (ca. 1535 cm1), have all increased, but the effect
on msym nitro is more difficult to determine as there
are many overlapping bands in this region. The mC–O
stretch of the alcohol on both the lactone (in hncH)
and the phenoxy (in hmncH) rings also decreased by
80–100 cm1 upon formation of the complexes. Both
of these shifts would be consistent with bonding to
the metal being through the nitro and hydroxyl/phen-
oxy oxygen groups, to form a 6-membered chelate
ring. There was also a significant shift in the mC@O
bond, which lowers by ca. 60 cm1 upon complexation
for the hncH complexes but hardly at all for the
hmncH complex. This is not too surprising,as in the
hncH complexes the carbonyl is located on the same
lactone ring as the ligand binding site. Such a large
shift in mC@O in similar complexes has been taken as
evidence that complexation occurs through the car-
bonyl oxygen atom [15–20]. It has recently been
shown that, in the case of 7-hydroxy-4-methylcouma-
rin complexes of Na+, Cu+ and H+, where bonding
is through the phenolate anion, coordination to the
cation induced polarisation on the lactone ring and re-
sulted in significant shifts in the carbonyl stretching
frequency [31]. In the mixed-ligand species 4 distinc-
tive bands for the phen ligand were evident at 1421,
853 and 738 cm1.
The 1H NMR solution spectra of the Ag(I) com-
plexes show resonance shifts for all of the complexes
relative to the uncoordinated ligand (see Fig. 1 for
atom numbering). For the hncH complexes, coordina-
tion through the nitro and phenoxy oxygen atoms of
the lactone ring results in upfield shifts of between
0.03 and 0.06 ppm for the protons on the fused aro-
matic ring, particularly so for the mixed hncH–phen
complex 4. Also of note is the disappearance of the
exchangeable hydrogen peak for the now deproto-
nated and coordinated hydroxy oxygen atom of the
complexed ligands. The 13C NMR spectra show that
the carbon atoms on the lactone ring which is at-
tached to the nitro groups experience the most signif-
icant downfield shift (ca. 40 ppm) upon coordination
of the Ag(I) cation.
The 1H NMR spectrum of the Ag(I) hmncH com-
plex 3 shows significant downfield shifts (ca. 0.15–
0.7 ppm) for all protons, particularly those on the aro-
matic ring, when compared to the metal-free ligand.
Similar shifts were noted in the 13C NMR spectrum,
with the largest being for the carbon atoms attached
to the hydroxy and nitro groups (15 and +40 ppm,
respectively). There was no significant shift observed
for the carbonyl carbon atom upon coordination to
the metal. The 1H NMR spectrum of the hncH–phen
complex 4 has additional signals at 9.18, 8.80, 8.05
and 8.00 ppm corresponding to the presence of the
two phen ligands and the integrals confirm the 2:1
phen:coumarin ratio.
3.2. X-ray crystal structure of [Cu(hnc)2(H2O)2] Æ
2H2O (1)
The X-ray crystal structure of 1 is shown in Fig. 2.
Selected bond lengths and angles are given in Table 2.
Although Kumar et al. [14] had previously isolated a
Cu(II) complex of hncH, their assignment of the struc-
ture isolated is quite different to that reported herein.
The metal center in 1 exhibits octahedral geometry,
comprising two bidentate hnc ligands and two
monodentate water ligands. The water molecules are
trans to one another with Cu–O (water) bond lengths
of 1.9557(14) and 1.9957(13) A˚ to O11 and O12,
respectively, and an O12–Cu–O11 bond angle of
177.76(6). The hnc ligands are coordinated to the
metal via the deprotonated hydroxy group and one
oxygen of the nitro group. The geometry of the li-
gands relative to one another is trans, as is the geom-
etry of the individual binding sites relative to
one another [O5–Cu–O10 179.37(5), O1–Cu–O6
176.96(5)]. The Cu–O (hnc) bond lengths are unre-
markable as they lie in a similar range to previously
reported distances [32,33]. The packing structure dia-
gram for 1 (Fig. 3), illustrates the extent of hydro-
gen-bonding in the gross array, with the lactone
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Fig. 1. Structures of the hncH and hmncH ligands used in this study
showing atom numbering used in (a) 1H NMR spectral assignments
and (b) 13C NMR spectral assignments.
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carbonyl and the nitro group interacting with the lat-
tice water molecules which are, in turn, involved in
hydrogen-bonding to the two ligated waters. This
extensive H-bonding within the crystal could account
for the observed shift in the IR carbonyl stretching
frequency.
3.3. X-ray crystal structure of [Ag(4-OH-3-NO2-C)]
(2)
The X-ray crystal structure of 2 is shown in Fig. 4
and selected geometric data are given in Table 3. The
complex is polymeric, with each silver having seven con-
tacts within its coordination sphere and being bonded to
four separate coumarin molecules. In particular, within
the asymmetric unit there is one axial Ag–O(O1) and
one equatorial Ag–O(O5) bond, at 2.5102(17) and
2.3531(16) A˚, respectively. Axial metal coordination is
completed by an Ag–C6 interaction (2.527(2) A˚) to
the coumarin moiety generated by the 1  x, 1/2 + y,
1/2  z symmetry operation. While this Ag–C bond is
interesting, comparable interactions have been
Fig. 2. Crystal structure of [Cu(hnc)2(H2O)2] Æ 2H2O. Ellipsoids are represented at the 30% probability level.
Table 1
Crystal data and structure refinement for 1 and 2
Compound 1 2
Empirical formula C18H16CuN2O14 C9H4AgNO5
Formula weight 547.87 314.00
Crystal system monoclinic monoclinic
Space group P1/c P1/c
Unit cell dimensions
a (A˚) 8.7610(1) 8.8770(1)
b (A˚) 15.1230(2) 6.7120(1)
c (A˚) 15.8230(2) 14.4640(2)
b () 103.489(1) 101.899(1)
U (A˚3) 2038.60(4) 843.28(2)
Z 4 4
Dc (g cm
3) 1.785 2.473
l (mm1) 1.156 2.394
F (000) 1116 608
Crystal size (mm) 0.30 · 0.13 · 0.13 0.35 · 0.30 · 0.10
h Range for data collection () 3.78–30.01 4.18–30.03
Index ranges 12 6 h 6 12;
21 6 k 6 21;
22 6 l 6 22
12 6 h 6 12;
9 6 k 6 9;
20 6 l 6 20
Reflections collected 39853 17349
Independent reflections [Rint] 5916 [0.0388] 2460 [0.0477]
Reflections observed (I > 2r(I)) 5168 2351
Absorption correction semi-empirical
from equivalents
semi-empirical
from equivalents
Maximum and minimum
transmission
0.90, 0.83 0.79, 0.65
Data/restraints/parameters 5916/8/349 2460/0/146
Goodness-of-fit on F2 1.054 1.127
R1, wR2 [I > 2r(I)] 0.0329, 0.0853 0.0271, 0.0708
R indices (all data) 0.0409, 0.0894 0.0299, 0.0719
Largest difference in peak
and hole (e A˚3)
0.661, 0.560 1.071, 1.686
Table 2
Selected bond lengths (A˚) and angles () for [Cu(hnc)2(H2O)2] Æ 2H2O
(1)
Cu(1)–O(10) 1.9300(11) Cu(1)–O(5) 1.9304(11)
Cu(1)–O(11) 1.9557(14) Cu(1)–O(12) 1.9957(13)
Cu(1)–O(6) 2.2764(13) Cu(1)–O(1) 2.3254(12)
O(10)–Cu(1)–O(5) 179.37(5) O(10)–Cu(1)–O(11) 89.42(5)
O(5)–Cu(1)–O(11) 90.23(6) O(10)–Cu(1)–O(12) 91.51(5)
O(5)–Cu(1)–O(12) 88.86(5) O(11)–Cu(1)–O(12) 177.76(6)
O(10)–Cu(1)–O(6) 79.51(5) O(5)–Cu(1)–O(6) 100.00(5)
O(11)–Cu(1)–O(6) 94.54(7) O(12)–Cu(1)–O(6) 87.63(6)
O(10)–Cu(1)–O(1) 102.40(4) O(5)–Cu(1)–O(1) 78.11(5)
O(11)–Cu(1)–O(1) 87.86(6) O(12)–Cu(1)–O(1) 89.95(5)
O(6)–Cu(1)–O(1) 176.96(5)
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previously reported for Ag(I) polycyclic aromatic com-
plexes [39]. In the equatorial plane, each silver is also
coordinated to two lactone oxygens (O3) from neigh-
bouring molecules in the lattice. [Ag–O3a 2.4733(15),
Ag–O3b 2.4970(16) A˚; asymmetry operator x, 1/2 + y,
1/2  z, bsymmetry operator x, 1/2  y, z  1/2]. There
are also two potential longer contacts to the metal in
the equatorial plane. [Ag–O2b 2.6784(17), Ag–O4c,
2.7841(13) A˚; bsymmetry operator x, 1/2 + y, z  1/2,
csymmetry operator x, 1/2  y, 1/2  z]. Bond dis-
tances for Ag–OOH, Ag–OC@O, Ag–ONO and Ag–C are
similar to others previously reported [34–36]. The axial
bond angles of the C6000(aryl)–Ag–O1 (nitro) (172.5),
the O5(hydroxy)-Ag–O3 0(carbonyl) (72) and O5(hy-
droxy)–Ag–O1(nitro) (66.8), as well as others given in
Table 3, suggests that the geometry at the metal centre
is best described as a distorted pentagonal bipyramid.
3.4. Antimicrobial results
The metal-free ligands and complexes were screened
for their in vitro antimicrobial activities against selected
Gram positive bacteria {S. aureus (SA), methicillin-resis-
tant S. aureus (MRSA), S. simeoleus (S.Sim.), M. luteus
(Ml)} and Gram negative bacteria {E. coli (E.Coli),
B. olenius (BO), P. agglumerans (PA)} and also against
the pathogenic fungus C. albicans (Can). The results
are presented in Table 4 as MIC80 values (in lM) which
is the minimum concentration required to inhibit 80% of
the growth of the microbe at 30 C.
Fig. 3. Crystal packing structure of [Cu(4-hnc)2(H2O)2] Æ 2H2O.
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The metal-free ligands, [Cu(hnc)2(H2O)2] Æ 2H2O (1)
and the simple Cu(II) salt showed no significant anti-
bacterial or antifungal activity. For the silver-contain-
ing samples the antimicrobial activity of the simple
salt AgNO3 was, almost without exception, superior
to that of [Ag(hnc)] (2) and [Ag(hmnc)] (3) across all
of the bacterial and the fungal species studied. How-
ever, one interesting exception to that trend was in
the activity of complexes 2 and 3 against the clinically
important bacterium MRSA. [Ag(hmnc)] (3) was
approximately four times more active that AgNO3
against MRSA. In general however, the phen-contain-
ing complex [Ag(phen)2hnc] (4) displayed the greatest
inhibitory effects against all of the microbes studied,
with its performances against the bacterium MRSA
and the fungal isolate C. albicans being the most em-
phatic. The phen ligand itself also showed considerable
activity against test strains, but complex 4 was still six
times more active against MRSA and three times more
active against C. albicans, than phen and was compara-
Fig. 4. Crystal structure of [Ag(4hnc)]. Ellipsoids are represented at the 30% probability level. Atoms in asymmetric unit denoted by unprimed labels.
Singly, doubly and triply primed atom labels denote atoms generated via the 1  x, 1/2 + y, 1/2  z, x, 1/2 + y, 1/2  z and x, 1/2  y, 1/2 + z
symmetry operations.
Table 3
Selected bond lengths (A˚) and angles () for [Ag(hnc)] (2)
Ag(1)–O(5) 2.3531(16) Ag(1)–O(3)#1 2.4733(15)
Ag(1)–O(3)#2 2.4970(16) Ag(1)–O(1) 2.5102(17)
Ag(1)–C(6)#3 2.527(2) C(6)–Ag(1)#6 2.527(2)
O(3)–Ag(1)#4 2.4733(15) O(3)–Ag(1)#5 2.4970(16)
O(5)–Ag(1)–O(3)#1 148.98(5) O(5)–Ag(1)–O(3)#2 123.85(6)
O(3)#1–Ag(1)–O(3)#2 71.79(6) O(5)–Ag(1)–O(1) 66.80(5)
O(3)#1–Ag(1)–O(1) 89.93(5) O(3)#2–Ag(1)–O(1) 86.43(5)
O(5)–Ag(1)–C(6)#3 117.14(6) O(3)#1–Ag(1)–C(6)#3 83.99(6)
O(3)#2–Ag(1)–C(6)#3 95.79(7) O(1)–Ag(1)–C(6)#3 172.50(6)
Ag(1)#4–O(3)–Ag(1)#5 108.21(6)
Table 4
Antimicrobial activity given as the concentration of compound required to inhibit cell growth by 80% [MIC80 (lM)]
Compound SA MRSA S.Sim Ml E.Coli BO PA C. albicans 10231
HncH >500 >500 >500 >500 >500 >500 >500 >500
HmnH >500 >500 >500 >500 >500 >500 >500 >500
1,10-Phen 23.9 14.7 20 29.8 >500 >500 41.4 15
Cu(ClO4)2 Æ 6H2O >500 >500 >500 >500 >500 >500 >500 >500
AgNO3 69.4 124.1 16.9 64.6 69.5 31.4 67.7 66.8
1 >500 >500 >500 >500 >500 >500 >500 >500
2 143.3 114.6 124.2 70.1 41.1 82.8 117.8 219.6
3 129.3 32.6 141.1 59.4 151.6 136.9 157.4 246.6
4 32.1 2.2 16.9 16.0 44.7 16.9 15.3 4.5
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ble in activity to the commercially available fungicides
clortrimazole and ketoconazole (MIC80 = 5.5 and
25 lM, respectively). We and others have reported
the anti-Candida activity of several other phen com-
plexes [37–39]. The activity of phen complexes is be-
lieved to be related to the abstraction by the phen
ligands of metal ions present in trace amounts in the
growth media, and that it is the resulting metal-phen
complexes that are responsible for the high anti-
Candida activity. The present work has shown that
while the presence of phen in a complex does indeed in-
crease the anti-Candida activity of the resulting com-
plex, it is likely that the coumarin-metal moieties
have a role to play as well.
4. Conclusions
The results presented here demonstrate that a num-
ber of potent anti-bacterial and antifungal agents have
been synthesised. In particular, [Ag(phen)2hnc] (4)
shows good activity against methicillin-resistant
S. aureus (MRSA) but not against the drug susceptible
variant S. aureus. Complex 4 is also active against C.
albicans and is more potent than metal-free phen.
Since MRSA is frequently associated with superficial
infections of wounds and ulcers the ability of 4 to in-
hibit the growth of MRSA might indicate a possible
clinical use for the complex. It is possible that the
complex compound could be incorporated into an
ointment or cream for topical application to the af-
fected area to retard the development and dissemina-
tion of infection. 4 is active against C. albicans and
compares favourably with some of the conventional
anti-fungal agents, such as clortrimazole and ketocon-
azole. With drug-resistant strains of microbes increas-
ing in importance in the clinical setting, these new
compounds may offer alternative candidates to those
compounds presently in clinical use. A study is cur-
rently under way to elucidate the mechanism of action
of the most active compounds.
5. X-ray crystallography
Single crystals of 1 and 2 were analysed at 150 K
using a Nonius Kappa CCD diffractometer equipped
with graphite monochromated Mo Ka radiation. De-
tails of the data collections, solutions and refinements
are given in Table 1. Both structures were solved using
SHELXS-97 [29] and refined using full-matrix least-squares
in SHELXL-97 [30]. Convergence was uneventful, with the
following points of note.
The asymmetric unit in 1 was seen to contain two
molecules of water in addition to one full molecule of
the copper complex. The water hydrogen atoms were
all located and refined at distances of 0.89 A˚ from the
relevant parent atoms. In 2 the asymmetric unit is com-
prised of one full ligand moiety, bonded in bidentate
fashion to a silver atom. Both refinements were imple-
mented using full-matrix least-squares.
Crystallographic data for 1 and 2 have been depos-
ited with the Cambridge Crystallographic Data Centre
as supplementary publications CCDC 253929 and
253930, respectively. Copies of the data can be obtained
free of charge on application to CCDC, 12 Union Road,
Cambridge CB2 1EZ, UK [fax: (+44) 1223 336033,
e-mail: deposit@ccdc.cam.ac.uk].
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